id,tipo,text_start,text_end,text
10210927,MajorClaim,45,148,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,Premise,632,906,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,Premise,907,1040,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,Premise,1041,1125,"whereas neoplasm grew according to an almost exponential trend in untreated patients"
10210927,Premise,1132,1171,"survival was better in treated patients"
10210927,Premise,1329,1396,"Karnofsky performance score was particularly high in both patients."
10210927,Claim,1425,1479,"octreotide is endowed with antiproliferative activity."
10210927,Claim,1494,1607,"octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour."
10403690,Claim,1526,1647,"combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC."
10403690,Premise,983,1044,"Partial response rates were 40 and 41.7% in IEP and MVP arms."
10403690,Premise,1045,1185,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,Premise,1186,1275,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,Premise,1276,1366,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,Premise,1367,1508,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
10506606,Premise,727,821,"The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006)."
10506606,Premise,822,968,"All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen."
10506606,Premise,969,1105,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,Premise,1106,1233,"DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041)."
10506606,Premise,1234,1355,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
10506606,Claim,1356,1544,"DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week."
10526263,Claim,1,173,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,Premise,1561,1698,"Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients)."
10526263,Claim,1708,1773,"the survival rates were by-and-large the same for the two groups."
10526263,Claim,1774,1873,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,Claim,1874,2015,"The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same."
10526263,Claim,2016,2162,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,Premise,1263,1409,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,Premise,1410,1560,"A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients)."
11346336,Premise,1287,1583,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,Premise,1584,1676,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,Premise,1677,1782,"Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded."
11346336,Premise,1783,1983,"The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days."
11346336,Premise,1984,2281,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,Premise,2282,2352,"No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,Premise,2353,2524,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,Claim,2525,2790,"Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day."
11346336,Claim,2791,2912,"Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication."
11370551,Claim,188,273,"In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,Claim,90,187,"Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+)."
11370551,Premise,1841,1962,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,Premise,1964,2164,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,Premise,2165,2324,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,Premise,2325,2746,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,Claim,2747,2796,"The patient accrual of our trial is satisfactory,"
11370551,Claim,2797,2898,"neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity."
11387359,Premise,1008,1140,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,Premise,1141,1354,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,Premise,1420,1524,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,Premise,1529,1628,"Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa."
11387359,Premise,1629,1675,"Adverse events were comparable between groups."
11387359,Claim,1676,1816,"Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy."
11387359,Claim,1817,1923,"Encouraging results regarding increased survival warrant another trial designed to confirm these findings."
11438417,Premise,945,1084,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,Premise,1085,1183,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,Premise,1184,1330,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,Claim,1331,1389,"Fludarabine was consistently a better treatment than ChOP,"
11438417,Premise,1390,1513,"except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment."
11438417,Premise,1528,1672,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,Claim,1690,1801,"patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP."
11438417,Claim,1802,1850,"These two treatments are always superior to CAP."
11970761,Claim,1,96,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,Premise,982,1337,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,Premise,1338,1507,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,Premise,1508,1685,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,Claim,1686,1774,"Denileukin diftitox was not associated with any clinically significant myelosuppression."
11970761,Claim,1775,1982,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
12004217,Claim,1,116,"Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer."
12004217,Premise,117,327,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,Premise,1512,1633,"problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery."
12004217,Premise,1634,1753,"The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day)."
12004217,Premise,1767,1935,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,Premise,1942,2043,"the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch."
12004217,Claim,2044,2169,"The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis."
12004217,Claim,2183,2286,"stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group."
12004217,Claim,2357,2515,"we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility."
12004217,Premise,2296,2356,"because neorectal capacity decreased equally in both groups,"
12011126,Premise,818,1065,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively."
12011126,Premise,1066,1170,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001)."
12011126,Premise,1171,1291,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);"
12011126,Premise,1292,1373,"this improvement correlated with an increase in Hb concentration (> or = 2 g/dL)."
12011126,Claim,1447,1674,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
12047964,Premise,798,967,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,Premise,688,797,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,Premise,968,1138,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,Premise,1139,1302,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,Claim,1303,1408,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,Claim,1409,1503,"The Lokich regimen was associated with more central line complications and hand-foot syndrome."
12047964,Claim,1504,1622,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,Claim,1623,1685,"but resulted in greater toxicity and inferior quality of life."
12118024,Premise,1011,1188,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,Premise,1189,1345,"Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone."
12118024,Premise,1346,1509,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,Premise,1566,1665,"There were no differences in the proportions of patients in the two groups that reported worsening."
12118024,Claim,1666,1861,"Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone."
12118024,Premise,1510,1565,"but the differences were not statistically significant."
12118027,Premise,550,745,"The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04)."
12118027,Premise,746,849,"Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14)."
12118027,Premise,850,940,"Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34)."
12118027,Premise,941,975,"Toxicities in both arms were mild."
12118027,Premise,976,1106,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,Premise,1107,1155,"No patients developed hemolytic uremic syndrome."
12118027,Claim,1156,1278,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,Premise,1279,1358,"although there was no statistically significant difference in QOL between arms."
12118027,Claim,1533,1675,"These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer."
12118027,Claim,1359,1478,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,Claim,1479,1532,"but this did not translate into a survival advantage."
12657097,Premise,812,912,"At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,Premise,913,1004,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,Premise,1005,1226,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,Premise,1227,1441,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,Claim,1604,1726,"This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy."
12657097,Premise,1442,1603,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
12711121,Premise,839,974,"Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression."
12711121,Premise,975,1092,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,Premise,1093,1331,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,Premise,1332,1509,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,Premise,1510,1656,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,Claim,1657,1755,"Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR."
12711121,Claim,1756,1879,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,Premise,1880,2022,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12721238,Claim,1,177,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,Claim,178,254,"These physical changes can negatively affect health-related quality of life."
12721238,Claim,255,403,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,Premise,934,1112,"Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group."
12721238,Premise,1113,1266,"Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group."
12721238,Premise,1267,1448,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,Claim,1449,1602,"Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy."
12721238,MajorClaim,1603,1693,"This form of exercise can be an important component of supportive care for these patients."
12721239,Premise,1073,1143,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,"
12721239,Premise,1144,1283,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001)."
12721239,Premise,1284,1448,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001)."
12721239,Premise,1449,1576,"Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01)."
12721239,Claim,1577,1696,"Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors."
12748244,Premise,579,633,"Efficacy was similar for the 250- and 500-mg/d groups."
12748244,Premise,634,1011,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,Premise,1124,1252,"Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea."
12748244,Premise,1012,1123,"Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response."
12748244,Premise,1253,1321,"Drug-related toxicities were more frequent in the higher-dose group."
12748244,Premise,1322,1439,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,Claim,1440,1580,"Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients."
12748244,Claim,1581,1631,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,Claim,1632,1735,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12783373,Claim,1,193,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,Premise,1291,1408,"Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN."
12783373,Premise,1409,1566,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,Premise,1567,1704,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,Premise,1705,1815,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,Claim,1816,1907,"Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML."
12783373,Claim,1921,2010,"patients who crossed over to imatinib reported higher QoL than those who remained on IFN."
12837811,Premise,533,701,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,Premise,702,791,"The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients."
12837811,Premise,792,890,"Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029)."
12837811,Premise,891,1075,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,Premise,1076,1179,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,Premise,1180,1276,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,Premise,1277,1426,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,Claim,1427,1502,"DC resulted in a more favorable overall response and survival rate than VC."
12837811,Claim,1503,1611,"Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC."
12837811,Claim,1612,1807,"These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC."
12915593,Premise,507,723,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,Premise,724,821,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,Premise,822,975,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,Premise,976,1142,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,Premise,1143,1268,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,Premise,1269,1357,"The number of hospital admissions and the number of days in hospital were not different."
12915593,Claim,1358,1410,"In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,Premise,1411,1495,"but this did not lead to a higher complete response rate or better overall survival."
12915593,Claim,1496,1537,"G-CSF did not prevent serious infections."
12925071,Claim,90,179,"Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+)."
12925071,Premise,1516,1623,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,Premise,1625,1799,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,Premise,1800,1959,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,Premise,1960,2264,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,Claim,2265,2313,"The patient accrual to the trial is satisfactory"
12925071,Claim,2315,2402,"Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity."
15139072,MajorClaim,1,164,"Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life."
15139072,Premise,1059,1234,"Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004)."
15139072,Premise,1235,1405,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,Premise,1406,1533,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,Claim,1534,1693,"The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes."
15139072,Premise,1694,1779,"However, there were no significant differences between groups for the other outcomes."
15157043,Claim,1,114,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,Premise,1045,1091,"No patient in G1 developed a thrombotic event."
15157043,Premise,974,1044,"In all four patients, Hgb levels were normal at the time of the event."
15157043,Premise,1092,1206,"There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2."
15157043,Premise,1285,1442,"The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials."
15157043,Claim,1443,1521,"This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,Claim,1522,1619,"but the small sample size and possible predisposing risk factors preclude definitive conclusions."
15226325,Premise,1042,1136,"there were no statistically significant differences in HRQOL between the two treatment groups."
15226325,Premise,1137,1227,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,"
15226325,Premise,1228,1355,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time."
15226325,Claim,1356,1428,"Overall, global quality of life was maintained in both treatment groups."
15226325,Claim,1429,1625,"This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions."
15226773,Claim,1,141,"Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes."
15226773,Premise,1037,1199,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC."
15226773,Premise,1200,1318,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195)."
15226773,Claim,1319,1546,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area."
15226773,Claim,1547,1699,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
15251160,Claim,1,163,"Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life."
15251160,Premise,917,958,"Ibandronate was generally well tolerated."
15251160,Premise,959,1101,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,Premise,1102,1201,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,Premise,1202,1342,"A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status."
15251160,Premise,1343,1616,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,Premise,1617,1727,"Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group."
15251160,Claim,1728,1923,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15274068,Claim,1,104,"Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental."
15274068,Premise,105,213,"Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue."
15274068,Premise,752,907,"There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18)."
15274068,Premise,908,1104,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,Premise,1105,1331,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,Premise,1332,1534,"Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy."
15274068,Claim,1535,1673,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,Claim,1674,1749,"Improved physical functioning may be necessary to combat radiation fatigue."
15284262,Premise,938,1105,"Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002)."
15284262,Premise,1106,1195,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,Premise,1196,1265,"There was no difference in median survival (8.8 months v 9.7 months)."
15284262,Premise,1266,1342,"Grade 3 to 4 anemia and neutropenia were more common in the combination arm."
15284262,Premise,1343,1393,"There was no significant difference in QOL scores,"
15284262,Premise,1394,1594,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,Claim,1595,1687,"C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL."
15288288,Premise,862,941,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,Premise,942,1007,"but long-term relief of dysphagia was better after brachytherapy."
15288288,Premise,1008,1208,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,Premise,1209,1425,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,Premise,1426,1478,"This decline was more pronounced in the stent group."
15288288,Premise,1479,1672,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,Premise,1673,1774,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,Premise,1775,1823,"general pain levels increased to a minor extent."
15288288,Claim,1824,1963,"The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer."
15288288,Claim,1964,2066,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,Premise,2067,2202,"since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales."
16446330,Premise,1093,1311,"Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm."
16446330,Premise,1312,1536,"Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT."
16446330,Claim,1537,1610,"The TC regimen achieved better QoL outcomes compared with the PT regimen."
16446330,Claim,1611,1734,"Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy."
16446335,Premise,933,1130,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54)."
16446335,Premise,1131,1281,"This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009)."
16446335,Premise,1282,1417,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period."
16446335,Claim,1418,1590,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL"
16446335,Claim,1592,1749,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
16462503,Claim,1,82,"Fatigue has a significant impact on the quality of life (QOL) of cancer patients."
16462503,Claim,83,201,"Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment."
16462503,Premise,1298,1383,"Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,Premise,1384,1597,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,Premise,1598,1748,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,Premise,1749,1855,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,Premise,1856,1958,"Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline"
16462503,Claim,1960,2044,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,Claim,2049,2165,"there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment."
16490846,Premise,946,1185,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,Premise,1186,1319,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,Premise,1320,1465,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,Claim,1466,1579,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,Premise,1589,1672,"because a 5-year period is normally required to determine definite recurrence rates"
16490846,Claim,1674,1754,"it is possible that MMS may become a cost-effective treatment for recurrent BCC."
16505413,Claim,90,219,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,Premise,511,739,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,Premise,740,846,"Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group."
16505413,Premise,847,974,"Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments."
16505413,Premise,975,1179,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,Premise,1180,1301,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,Premise,1302,1449,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,Claim,1450,1593,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,Claim,1594,1744,"Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents."
16524633,MajorClaim,1,52,"Morbidity is an important issue in cancer research."
16524633,Claim,53,241,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,Claim,242,317,"but like other toxicity scoring systems it has not been formally validated."
16524633,Premise,1075,1172,"The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints."
16524633,Premise,1173,1252,"The conceptually similar endpoints of the two methods correlated significantly."
16524633,Premise,1253,1380,"The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree."
16524633,Premise,1381,1594,"The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints."
16524633,Premise,1595,1696,"A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected."
16524633,Claim,1697,1920,"The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints."
16524633,Claim,1921,2045,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16571129,Claim,1,269,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,Claim,362,406,"the treatments are not always well-accepted,"
16571129,Claim,411,526,"patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits."
16571129,Premise,1569,1679,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,Premise,1680,1772,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,Premise,1773,1850,"The Flexitouch device was apparently well-tolerated and accepted by patients."
16571129,Premise,1851,1972,"Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;"
16571129,Premise,1973,2069,"there were no statistical differences in scores when the two treatment modalities were compared."
16571129,Claim,2070,2267,"This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema."
16571129,Claim,2268,2389,"The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted."
17674351,Claim,1,108,"Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome."
17674351,Premise,762,884,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,Premise,885,986,"Previously validated appetite questionnaires revealed negligible improvements in both treatment arms."
17674351,Premise,987,1124,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,Premise,1134,1344,"preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%)."
17674351,Premise,1345,1392,"Infection rates were negligible in both groups."
17674351,Premise,1393,1627,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,Claim,1628,1779,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17690882,Premise,797,862,"KPS was improved from baseline to post-chemotherapy in both arms."
17690882,Premise,660,796,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,Premise,863,914,"QOL data showed improvement in some symptom scores,"
17690882,Premise,915,1027,"but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment."
17690882,Premise,1028,1103,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,Premise,1104,1276,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,Claim,1277,1418,"Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC."
17690882,Claim,1419,1578,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17717452,Claim,127,208,"More recently coloplasty has been advocated as an alternative to a colonic pouch."
17717452,Premise,1235,1288,"Twenty-three (7.4%) died within 24 months of surgery."
17717452,Premise,1289,1368,"No significant difference was observed in the complications among the 4 groups."
17717452,Premise,1453,1526,"There was no difference in bowel function between the CP-1 and SA groups."
17717452,Premise,1527,1640,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,Premise,1641,1691,"Other parameters were not statistically different."
17717452,Premise,1692,1754,"QOL scores at 24 months were similar for each of the 4 groups."
17717452,Claim,1755,1907,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,Claim,1908,2029,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17848814,Claim,1,123,"Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment."
17848814,Premise,124,248,"The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies."
17848814,Premise,945,1034,"There was an improvement of muscle strength at the end of rehabilitation for both groups."
17848814,Premise,1035,1110,"The increase from t1 to t2 was significantly higher for the training group."
17848814,Premise,1111,1213,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,Premise,1214,1300,"but further improvement in the follow-up (t3) was only observed in the training group."
17848814,Premise,1301,1425,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,Claim,1426,1642,"Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients."
17852440,Claim,1,144,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,Claim,145,249,"Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO)."
17852440,Premise,1335,1494,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,Premise,1495,1657,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,Premise,1658,1797,"The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients)."
17852440,Premise,1798,2082,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,Premise,2083,2131,"QW epoetin-alpha was found to be well tolerated."
17852440,Claim,2132,2335,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,Claim,2336,2498,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17876009,Premise,740,988,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care."
17876009,Premise,1128,1458,"patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale."
17876009,Claim,1459,1630,"This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress."
17876009,Claim,1631,1776,"Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress."
18448745,Premise,1326,1366,"No serious adverse events were reported."
18448745,Premise,1367,1469,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days."
18448745,Claim,1597,1677,"In this small study, CDB-2914 was well-tolerated without serious adverse events."
18448745,Claim,1678,1749,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
18448745,Premise,1470,1596,"CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment."
18457329,Premise,821,1165,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039)."
18457329,Premise,1166,1256,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group"
18457329,Premise,1257,1300,"but did not reach statistical significance."
18457329,Claim,1535,1652,"Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors."
18457329,Premise,1301,1534,"The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage."
18485819,MajorClaim,1,145,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,MajorClaim,146,262,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,Premise,1688,1883,"The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002)."
18485819,Premise,1884,2049,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,Premise,2050,2170,"The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001)."
18485819,Premise,2171,2349,"Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001)."
18485819,Premise,2350,2519,"The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001)."
18485819,Claim,2520,2702,"The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects."
18485819,MajorClaim,2703,2859,"Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer."
18520802,Claim,1546,1691,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
18520802,Claim,1692,1827,"but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient."
18520802,Premise,811,1002,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,Premise,1003,1146,"There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm."
18520802,Premise,1147,1240,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,Premise,1241,1346,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18589314,Premise,1103,1294,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,Claim,1909,2029,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,Premise,1837,1908,"The 24-month cumulative cost of UAE is lower than that of hysterectomy."
18589314,Premise,1589,1753,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,Premise,1295,1450,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,Premise,1451,1588,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18591549,Claim,1695,1792,"CBT for insomnia may be both clinically effective and feasible to deliver in real world practice."
18591549,Premise,1559,1694,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics."
18591549,Premise,1057,1167,"CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU."
18591549,Premise,1224,1419,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep)."
18591549,Premise,1420,1558,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue."
18591555,Premise,1113,1392,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344)."
18591555,Premise,1393,1503,"Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months)."
18591555,Premise,1654,1735,"Patients under combined treatment were at higher risk of severe thrombocytopenia."
18591555,Claim,1736,1866,"Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer."
18669464,Claim,1760,1833,"Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients."
18669464,Premise,1148,1373,"Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001)."
18669464,Premise,1385,1533,"differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01)."
20585099,Premise,901,982,"Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,Premise,983,1039,"although there was no difference between treatment arms."
20585099,Premise,1319,1408,"Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,Premise,1409,1455,"but thereafter it returned to baseline levels."
20585099,Premise,1456,1578,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,Premise,1579,1703,"but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE."
20585099,Claim,1704,1906,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,Claim,1916,1979,"PRE also affected sexual and some aspects of bowel functioning."
20600809,Premise,961,1181,"HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018)."
20600809,Premise,1182,1382,"HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05)."
20600809,Premise,1383,1482,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities."
20600809,Claim,1483,1603,"HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity."
20600809,Claim,1604,1685,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed."
20625123,Premise,706,935,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35)."
20625123,Premise,936,1116,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative."
20625123,Premise,1117,1426,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02)."
20625123,Premise,1427,1579,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm."
20625123,Claim,1580,1744,"This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue."
20631341,Premise,1585,1803,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037)."
20631341,Premise,1804,2092,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15)."
20631341,Claim,2093,2183,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P."
20631341,Premise,2184,2358,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P."
20631341,Claim,2359,2456,"The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up."
20651011,Premise,1353,1435,"Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,Premise,1436,1478,"except in mental fatigue in the WLC group."
20651011,Premise,1479,1683,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,Premise,1684,1879,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,Premise,1880,1973,"No significant differences in decline in fatigue were found between the PT+CBT and PT groups."
20651011,Premise,1974,2143,"Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention."
20651011,Claim,2144,2306,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,Claim,2323,2436,"cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training."
20679600,Premise,995,1158,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006)."
20679600,Premise,1159,1337,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items)."
20679600,Premise,1338,1488,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation."
20679600,Claim,1489,1539,"Arm morbidity was greater with SNAD than with SNR."
20679600,Claim,1614,1698,"this study demonstrates that initial problems with either surgery resolve over time."
20680680,Premise,645,789,"There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization."
20680680,Premise,790,946,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,Premise,947,1082,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,Premise,1083,1281,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,Claim,1282,1437,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20680680,Claim,1447,1570,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20697941,Premise,786,959,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),"
20697941,Premise,960,1106,"but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01)."
20697941,Premise,1117,1386,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01)."
20697941,Premise,1387,1560,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01)."
20697941,Claim,1561,1790,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
20733132,Premise,881,968,"Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm."
20733132,Claim,982,1064,"quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm."
20733132,Premise,1065,1128,"Although objective response was slightly higher in the TCG arm,"
20733132,Premise,1129,1223,"this did not translate into improved progression-free survival (PFS) or overall survival (OS)."
20733132,Premise,1224,1357,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,Premise,1358,1468,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,Claim,1469,1649,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,MajorClaim,1650,1727,"Therefore, we recommend no additional clinical use of TCG in this population."
20734132,Premise,1420,1495,"Upper limb volumes were also lower amongst intervention group participants."
20734132,Premise,811,1362,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02]."
20734132,Premise,1505,1681,"there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach)."
20734132,Claim,1682,1858,"Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency."
20809177,Premise,921,1075,"The dysfunction score was 58.9  15.0 after distal gastrectomy, 66.8  14.1 after total gastrectomy, and 62.4  21.6 after pylorus-preserving gastrectomy."
20809177,Premise,1076,1140,"These values differed significantly among the groups (P = .007)."
20809177,Premise,1141,1474,"Dysfunction scores according to postoperative activity status were 49.1  15.6 in 71 patients who resumed their activities, 56.9  15.7 in 39 patients with reduced activities, 57.3  8.8 in 15 patients with minimal activities, and 63.3  11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition."
20809177,Claim,1475,1702,"This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period."
20821047,Premise,1018,1173,"Tamoxifen-nave patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P=0.001)."
20821047,Premise,1174,1346,"There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs."
20821047,Premise,1347,1422,"Nearly 80% of patients reported one or more side effects with either agent."
20821047,Premise,1423,1508,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,Claim,1680,1716,"both AIs are equally well tolerated."
20821047,Claim,1717,1791,"There were no significant differences in QOL scores between the two drugs."
21892106,Premise,1127,1199,"The overall response rate was 51% in arm A and 38% in arm B (p = 0.147)."
21892106,Premise,1200,1247,"Grade 3/4 toxicity in both arms was acceptable."
21892106,Premise,1248,1363,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,Premise,1364,1408,"Patients in arm A had longer median survival"
21892106,Premise,1409,1492,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,Claim,1493,1539,"No difference in quality of life was observed."
21892106,Claim,1595,1733,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21901389,Premise,1382,1568,"Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation."
21901389,Claim,1569,1727,"The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition."
21901389,MajorClaim,1728,1896,"The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice."
21901389,Premise,1154,1381,"Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control."
21905158,Premise,1013,1163,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,Premise,1164,1216,"but the group differences were attenuated over time."
21905158,Premise,1217,1321,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,Premise,1322,1415,"Improvements in motivational readiness for PA were reported in the PA group only at 3 months."
21905158,Premise,1416,1552,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
21905158,Claim,1553,1705,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21911723,Premise,815,1005,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,Premise,1006,1179,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,Premise,1180,1289,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,Premise,1290,1523,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,Claim,1625,1677,"Octreotide did not add significant clinical benefit."
21911723,Claim,1678,1786,"High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome."
21911723,Claim,177,269,"octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence."
21993852,Premise,1033,1153,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.617.9, R-Y 8.616.3, p=0.02)."
21993852,Premise,1154,1282,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p=0.41)."
21993852,Premise,1283,1386,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.70.6 vs. 0.50.6, p=0.01)."
21993852,Claim,1387,1486,"The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction."
21993852,MajorClaim,1487,1621,"Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction."
23598172,Premise,1104,1286,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,Premise,1287,1457,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 57 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,Premise,1458,1574,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,Premise,1575,1609,"but decreased at end-of-treatment."
23598172,Premise,1610,1894,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,Premise,1895,2306,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,Claim,2409,2507,"investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group."
23598172,Claim,2508,2625,"These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma."
23598172,Claim,2316,2408,"overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23609927,Premise,912,1189,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,Premise,1190,1344,"Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02)."
23609927,Premise,1345,1458,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,Premise,1459,1557,"By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,Claim,1558,1727,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
23609927,Claim,1744,1796,"early interventions can be tailored for each gender."
23615094,Premise,1015,1159,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,Premise,1160,1238,"There was a significant reduction in tumor volume over time in the GKRS group."
23615094,Premise,1239,1355,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,Premise,1356,1432,"Symptom and QoL development did not differ significantly between the groups."
23615094,Claim,1433,1546,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,Claim,1547,1595,"Hearing is lost at similar rates in both groups."
23615094,Claim,1596,1659,"Symptoms and QoL seem not to be significantly affected by GKRS."
23632471,Premise,1077,1422,"Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time."
23632471,Claim,1423,1590,"The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients."
23632471,MajorClaim,1591,1754,"Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care."
23735703,Premise,1113,1167,"Although quality of life did not differ significantly,"
23735703,Premise,1168,1234,"chemotherapy compliance was significantly higher in the PRE group."
23735703,Premise,1018,1112,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,Premise,1235,1364,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,Premise,1365,1545,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,Premise,1546,1679,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,Premise,1689,1730,"the regimens' toxicity profiles differed."
23735703,Claim,1731,1883,"This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC."
23735703,Claim,1884,1995,"The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate."
23749688,Premise,760,980,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0mL kg(-1) min(-1) (95% CI -1.1-7.0)] and 3-month follow-up [2.1mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,Premise,981,1066,"although these differences did not achieve statistical significance (p values >0.14)."
23749688,Premise,1067,1374,"Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p=0.01) and 3-month follow-up (p=0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p=0.03) and 3-month follow-up (p=0.04)."
23749688,Premise,1375,1553,"Improvements in fatigue (p=0.01), total quality of life plus fatigue (p=0.04), and a composite physical functioning score (p=0.01) at the 3-month follow-up were also found."
23749688,Claim,1554,1777,"The PEACH trial suggests that 8weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
23749688,Claim,1778,1913,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23768153,Premise,1087,1245,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,Premise,1246,1355,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,Premise,1356,1431,"No statistically significant differences were found for secondary outcomes."
23768153,Premise,1432,1579,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,Claim,1580,1702,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,Claim,1703,1829,"but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required."
23768153,MajorClaim,1830,1951,"VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans."
23771714,Premise,909,1027,"PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95% CI 0.785-1.304); median 10.4months XP vs. 9.2months EP]."
23771714,Premise,1028,1164,"Overall survival was also similar [HR 1.027 (95% CI 0.740-1.424); median 22.0 vs. 26.1months], and response rate was 47% versus 42%."
23771714,Premise,1165,1320,"Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP."
23771714,Premise,1321,1360,"There were no major differences in QoL."
23771714,Claim,1423,1461,"first-line XP was active and feasible."
23771714,Claim,1361,1422,"Although, noninferiority of XP to EP was formally not proven,"
23771714,Claim,1462,1604,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23788218,Premise,1009,1181,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P=.04)."
23788218,Premise,1340,1437,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P=.04)."
23788218,Premise,1438,1669,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P=.009)."
23788218,Premise,1670,1865,"Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use."
23788218,Claim,1866,2023,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,Claim,2024,2199,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,Claim,2200,2299,"These findings have important implications for the treatment of patients with head and neck cancer."
23793805,Premise,878,1139,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,Premise,1140,1261,"Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012)."
23793805,Premise,1262,1406,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,Premise,1407,1498,"No clinically meaningful differences were detected between the two groups in long-term QOL."
23793805,Claim,1499,1579,"LADG showed similar DFS and OS compared to ODG in treating early gastric cancer."
23793805,Claim,1580,1644,"Marginal benefits in mild complications were observed with LADG."
23793805,Claim,1645,1731,"LADG did not show advantages over ODG regarding other complications and long-term QOL."
23803270,Premise,951,1037,"No statistically significant between-group differences were found in volume reduction;"
23803270,Premise,1038,1123,"however, all groups had clinically and statistically significant reduction in volume."
23803270,Premise,1124,1202,"No group differences were noted in psychological and physical symptoms or QOL;"
23803270,Premise,1203,1290,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,Premise,1291,1351,"Skin improvement was noted in each group that received LLLT."
23803270,Claim,1352,1435,"LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD."
23803270,Claim,1451,1531,"compression bandaging alone could account for the demonstrated volume reduction."
23803270,Claim,1532,1570,"APNs can effectively treat lymphedema."
23803270,Claim,1654,1725,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,Claim,1726,1828,"APNs with lymphedema certification can effectively treat this patient population with the use of LLLT."
23803270,Claim,1842,1921,"bioelectrical impedance and tape measurements can be used to assess lymphedema."
23814044,Premise,947,1072,"Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment."
23814044,Premise,1073,1236,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with ACTH and ACT at EOC, suggesting improved tolerability."
23814044,Premise,1237,1440,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an ACTH regimen, but was otherwise similar between arms."
23814044,Claim,1441,1645,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up."
23814044,Claim,1646,1781,"HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option."
23816967,Premise,1098,1210,"More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010)."
23816967,Premise,833,1097,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,Premise,1211,1341,"Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001)."
23816967,Premise,1342,1546,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,Premise,1547,1679,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,Claim,1680,1898,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,Claim,1899,1993,"Global health status/QoL was also improved over time with afatinib compared with chemotherapy."
23820680,Premise,1315,1438,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,Claim,1460,1533,"patients in whole stomach group suffered more severe nausea and vomiting."
23820680,Claim,1534,1717,"Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery."
23820680,Premise,900,1137,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,Premise,1149,1314,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,Premise,679,899,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,Premise,559,678,"The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31)."
23840308,Premise,1203,1416,"Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35)."
23840308,Claim,1417,1642,"Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective."
23840308,MajorClaim,1,60,"Delirium is a serious and common postoperative complication"
23860204,Premise,1194,1472,"Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001)."
23860204,Premise,1473,1564,"The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm."
23860204,Premise,1565,1707,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse."
23860204,Claim,1708,1841,"Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival."
23860204,Claim,1842,1921,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
24007947,MajorClaim,1,79,"Analgesia and early quality of recovery may be improved by epidural analgesia."
24007947,Premise,767,905,"More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01)."
24007947,Premise,906,1030,"Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)"
24007947,Premise,1035,1094,"there was no difference in serious adverse events (p=0.19)."
24007947,Premise,1095,1227,"Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group)."
24007947,Claim,1228,1316,"There was no difference in postoperative quality of life up to six months after surgery."
24007947,Claim,1317,1469,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,MajorClaim,1470,1581,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,Claim,1596,1678,"the present data do not support a quality of life benefit with epidural analgesia."
24019545,Premise,734,898,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,Premise,999,1199,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,Premise,1200,1323,"Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%)."
24019545,Premise,1324,1441,"AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%)."
24019545,Claim,1442,1600,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,MajorClaim,1,133,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24028441,Claim,1918,1990,"LRH provided lower pain scores after 36 h of observation in this series."
24028441,Claim,1991,2091,"The perioperative and serious postoperative complications ratios were comparable between the groups."
24028441,Premise,1722,1867,"LRH group mean pain score was significantly lower than ARH after 36 h of observation (P=0.044; mean difference score: 1.42; 95% CI: 0.04-2.80)."
24028441,Premise,1630,1721,"The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P=0.694."
24028441,Premise,1563,1629,"All of the transoperative complications occurred in the LRH group."
24028441,Premise,1418,1562,"Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications."
24028441,MajorClaim,44,214,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24038913,Claim,1455,1509,"QOL and survival data were similar for the two groups."
24038913,Claim,1510,1622,"A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children."
24038913,Premise,1344,1454,"Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results."
24038913,Premise,1228,1343,"Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05)."
24038913,Premise,960,1227,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29  6.5% and 37.5  7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35  8% and 36  8%, respectively."
24040301,MajorClaim,1,81,"Postcancer fatigue is a frequently occurring problem, impairing quality of life."
24040301,Claim,1625,1793,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
24040301,Premise,1225,1397,"Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group."
24040301,Premise,1398,1525,"Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group."
24040301,Premise,1526,1624,"No relation was found between postcancer fatigue and the studied volumetric and metabolic markers."
24127364,Claim,1638,1724,"This result may be due to higher rates of fatigue and gastrointestinal adverse events."
24127364,Claim,1337,1637,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
24127364,Premise,1141,1336,"Clinical adverse events of  grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,Premise,1046,1140,"A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%)."
24127364,Premise,911,1045,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,Premise,755,910,"The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo."
24151326,Premise,912,1127,"Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome."
24151326,Premise,1128,1329,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,Premise,1330,1464,"COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength."
24151326,Premise,1465,1557,"HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03)."
24151326,Premise,1558,1629,"No differences emerged for body composition or chemotherapy completion."
24151326,Claim,1630,1835,"A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes."
24178750,Claim,1652,1722,"Patients reported similar pain and satisfaction scores in both groups."
24178750,Claim,1723,1878,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,Premise,1069,1253,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,Premise,1254,1320,"Longer neutropenia duration was observed in all patient subgroups,"
24178750,Premise,1321,1367,"except for patients undergoing autologous HCT."
24178750,Premise,1368,1459,"There was no significant difference between groups in the occurrence of infection or death,"
24178750,Premise,1460,1564,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24246508,Claim,1854,1927,"No effects of the intervention were found for any outcome after one year."
24246508,Claim,1664,1779,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,Claim,1780,1853,"except for the bodily pain domain, four months after lung cancer surgery."
24246508,Claim,1582,1663,"We found no effect of the intervention on 6MWT or lung volumes at any time-point."
24246508,Premise,1484,1581,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,Premise,1129,1483,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
8648360,Premise,696,814,"A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment."
8648360,Premise,815,963,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,Premise,964,1030,"This difference of 2.0 kg was statistically significant (P = .04)."
8648360,Premise,1031,1113,"During the study, several areas of QL deteriorated in the total group of patients."
8648360,Claim,1114,1285,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,Premise,1286,1413,"The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed."
8648360,Claim,1414,1601,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,Claim,1602,1690,"However, general QL in the present study was not measurably influenced by MPA treatment."
8683634,MajorClaim,1,324,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,Claim,325,517,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,Premise,1326,1580,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,Premise,1581,1935,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,Claim,1936,2250,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,Claim,2251,2399,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,Premise,2400,2539,"since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects."
8683634,Claim,2540,2653,"The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations."
8839553,Claim,1,92,"Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;"
8839553,Premise,772,830,"No difference in survival was detected between the groups;"
8839553,Premise,831,1032,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,Premise,1033,1147,"Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm)."
8839553,Premise,1148,1241,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,Premise,1242,1327,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,Premise,1328,1445,"The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups."
8839553,Claim,1446,1589,"This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis."
8839553,Claim,1590,1737,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
9626213,Premise,663,970,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,Premise,971,1074,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,Premise,1075,1279,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,Claim,1280,1364,"The frequency and severity of other toxicities were comparable between the two arms."
9626213,Premise,1365,1481,"Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018)."
9626213,Premise,1482,1634,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,Premise,1635,1713,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,Premise,1950,2116,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,Claim,2117,2216,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,Claim,2217,2252,"Although survival was not improved,"
9626213,Claim,2253,2325,"arm B offers a better palliation for advanced NSCLC patients than arm A."
9640214,Premise,1200,1316,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,Premise,1317,1416,"Significant benefit in body image and satisfaction with treatment was observed in the BCT patients."
9640214,Premise,1417,1501,"No significant difference was observed in fear of recurrence between the two groups."
9640214,Premise,1502,1628,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,Claim,1629,1720,"Wide excision appeared to be the most important predictive factor for poor cosmetic result."
9640214,Claim,1721,1937,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9643663,Premise,454,731,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,Premise,732,890,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,Premise,891,1020,"Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity."
9643663,Premise,1021,1226,"'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen."
9643663,Claim,1236,1343,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,Claim,1344,1498,"An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease."
9643663,Claim,1607,1686,"'Casodex' 150 mg is less effective than castration in patients with M1 disease."
9643663,Claim,1696,1849,"'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile."
9643663,MajorClaim,1850,2012,"Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable."
